skip to Main Content

Cancer Services

Urogential and Prostate Cancer

Please see below all current urogenital and prostate cancer clinical trials of the Central Coast Cancer Centre.

Name: REAL PRO

Registry-based Study of Enzalutamide vs Abiraterone assessing cognitive function in ELderly patients with Metastatic Castration-Resistant Prostate Cancer.

Principal Investigator: Dr Malmaruha Arasaratnam
Study Coordinator: Bronwyn Raymond
Status: Recruiting
Condition: Prostate Cancer
External page link More information about REAL PRO

Name: SGNLV-005

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for unresectable locally advanced metastatic
solid tumours.

Principal Investigator: Dr Matthew Wong
Study Coordinator: Bronwyn Raymond
Status: Recruiting
Condition: Prostate Cancer
External page link More information about SGNLV-005

Name: CA045-009

A Phase 3 randomised study of neoadjuvant Nivolumab plus NKTR-214, versus Nivolumab alone versus standard of care in particular participants with muscle-invasive bladder cancer (MIBC) who are Cisplatin ineligible.

Principal Investigator: Dr Craig Kukard
Study Coordinator: Michelle Dixon
Status: Recruiting
Condition: Bladder Cancer
External page link More information about CA045-009

Name: CA209-650

A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer

Principal Investigator: Dr Craig Kukard
Study Coordinator: Michelle Dixon
Status: Closed
Condition: Prostate Cancer
External page link More information about CA209-650

Name: CA 209-7DX

A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX: CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 7DX)

Principal Investigator: Dr Matthew Chan
Study Coordinator: Bronwyn Raymond
Status: Recruiting
Condition: Prostate Cancer
External page link More information about CA 209-7DX

Name: COSMIC-021

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

Principal Investigator: Dr Craig Kukard
Study Coordinator: Richard Clayton
Status: Recruiting
Condition: Prostate Cancer
External page link More information about COSMIC-021

Name: DASL HiCaP

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomized phase 3 double-blind, placebo-controlled trial of adding Darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.

Principal Investigator: Dr Craig Kukard
Study Coordinator: Richard Clayton
Status: Recruiting
Condition: Prostate Cancer
External page link More information about DASL HiCaP

More information

For more information about medical oncology clinical trials, please contact the Nurse Unit Manager on 02 4320 9890 or see:

Internal page Research and Clinical Trials

Back To Top